Graf Acquisition Corp. IV (NYSE:GFOR) announced that it has signed a non-binding letter of intent to combine with clinical-stage biopharma company NKGen.
This announcement is not a pure teaser as Graf IV is not facing an imminent extension vote and currently has until May 25 on its clock. It does, however, signal something of a shift for a team that has focused on other technology sectors in its past deals.
Santa Ana, California-based NKGen has five pharmaceutical formulas that have each reached some stage of Phase I and Phase II clinical trials seeking potential therapies for cancer and neurodegenerative conditions like Parkinson’s and Alzheimer’s.
Its only active trial is a Phase I study of its SNK01-US01 candidate that attempts to use autologous natural killer cells to reduce advanced solid tumors in adults, according to its website.
Graf IV CEO James Graf served as an officer in several of the Eagle team SPACs before going solo with Graf Industrial, which combined with Velodyne Lidar in September 2020. Graf II and III ultimately withdrew their registration statements, but mentioned “mobility, technology [and] transportation” as their first target sectors.
The SPAC aims to release additional details about the transaction once a definitive agreement is reached, and Graf IV will remain in SPACInsider‘s “Searching” column until then.
Power & Digital Infrastructure II (NASDAQ: XPDB) has entered into a definitive agreement to combine with water harvesting company Montana Technologies at a pro forma enterprise value of approximately $500 million. Ronan, Montana-based Montana Technologies manufactures a dual-chamber design intended for a water harvesting process to solve legacy thermal constraints. The parties expect to close the deal in...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Carbon Revolution to supply its carbon fiber wheels for 2024 Range Rover, and Vast Solar awards Worley key engineering contracts Carbon Revolution to Supply its 23-inch Carbon Fiber Wheels for 2024 Range Rover Sport...
Phoenix Biotech (NASDAQ:PBAX) has entered into a definitive agreement to combine with pre-cliinical drug developer CERo at an enterprise value of $112 million. San Francisco-based CERo is developing a line of potential cancer treatments and expects to file its first investigational new drug (IND) application in 2024. The combined company is expected to trade on...
Hammerhead Energy Inc. (NASDAQ: HHRS), which combined with Decarbonization Plus IV, has announced the results of its substantial issuer bid that expired at 5:00 p.m. ET on June 2. Under the bid, HEI offered to purchase for cancellation up to 20 million of its warrants, representing approximately 70% of its total number of issued and outstanding warrants, to purchase...
Terms Tracker for the Week Ending June 2, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. As is typical of slow holiday weeks, this past week for SPACs was no exception. To wit, there were zero new S-1s filed, zero amendments...